This week, the Food and Drug Administration (FDA) announced its approval of a second species of carcass-eating fly for maggot wound therapy, a treatment that employs larvae to clean wounds effectively. Cuprina Holdings, a Singapore-based company, introduced its new therapeutic larvae, branded as MediFly Maggots, with this significant clearance.
Cuprina Holdings now holds the unique position of being the only company with FDA clearance for two different species of fly larvae in this therapeutic context. The newly approved species, Lucilia cuprina, commonly known as the Australian sheep blowfly, is closely related to Lucilia sericata, better known as the common green bottle fly. The latter has been the primary choice for maggot debridement therapy (MDT) since it received FDA approval in 2004.
Ronald Sherman, who is now the Medical and Scientific Director at Cuprina, was the first to secure FDA clearance for L. sericata. With the addition of L. cuprina to their offerings, Cuprina is poised to take a leading role in the expanding global market for maggot therapies, an area that is gaining traction due to its effectiveness in wound management.
